Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

393 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Keratin 18-deficiency results in steatohepatitis and liver tumors in old mice: A model of steatohepatitis-associated liver carcinogenesis.
Bettermann K, Mehta AK, Hofer EM, Wohlrab C, Golob-Schwarzl N, Svendova V, Schimek MG, Stumptner C, Thüringer A, Speicher MR, Lackner C, Zatloukal K, Denk H, Haybaeck J. Bettermann K, et al. Among authors: mehta ak. Oncotarget. 2016 Nov 8;7(45):73309-73322. doi: 10.18632/oncotarget.12325. Oncotarget. 2016. PMID: 27689336 Free PMC article.
High Keratin 8/18 Ratio Predicts Aggressive Hepatocellular Cancer Phenotype.
Golob-Schwarzl N, Bettermann K, Mehta AK, Kessler SM, Unterluggauer J, Krassnig S, Kojima K, Chen X, Hoshida Y, Bardeesy NM, Müller H, Svendova V, Schimek MG, Diwoky C, Lipfert A, Mahajan V, Stumptner C, Thüringer A, Fröhlich LF, Stojakovic T, Nilsson KPR, Kolbe T, Rülicke T, Magin TM, Strnad P, Kiemer AK, Moriggl R, Haybaeck J. Golob-Schwarzl N, et al. Among authors: mehta ak. Transl Oncol. 2019 Feb;12(2):256-268. doi: 10.1016/j.tranon.2018.10.010. Epub 2018 Nov 12. Transl Oncol. 2019. PMID: 30439626 Free PMC article.
Corrigendum to High Keratin 8/18 Ratio Predicts Aggressive Hepatocellular Cancer Phenotype12 [Translational Oncology Volume 12, Issue 2, February 2019, Pages 256-268].
Golob-Schwarzl N, Bettermann K, Mehta AK, Kessler SM, Unterluggauer J, Krassnig S, Kojima K, Chen X, Hoshida Y, Bardeesy NM, Müller H, Svendova V, Schimek MG, Diwoky C, Lipfert A, Mahajan V, Stumptner C, Thüringer A, Fröhlich LF, Stojakovic T, Nilsson KPR, Kolbe T, Rülicke T, Magin TM, Strnad P, Kiemer AK, Moriggl R, Haybaeck J. Golob-Schwarzl N, et al. Among authors: mehta ak. Transl Oncol. 2020 Feb;13(2):490-492. doi: 10.1016/j.tranon.2019.08.001. Transl Oncol. 2020. PMID: 32081369 Free PMC article. No abstract available.
Crimean-Congo Hemorrhagic Fever Virus for Clinicians-Diagnosis, Clinical Management, and Therapeutics.
Frank MG, Weaver G, Raabe V; State of the Clinical Science Working Group of the National Emerging Pathogens Training; Education Center’s Special Pathogens Research Network2; State of the Clinical Science Working Group of the National Emerging Pathogens Training Education Center’s Special Pathogens Research Network. Frank MG, et al. Emerg Infect Dis. 2024 May;30(5):864-873. doi: 10.3201/eid3005.231648. Emerg Infect Dis. 2024. PMID: 38666553 Free PMC article. Review.
Crimean-Congo Hemorrhagic Fever Virus for Clinicians-Epidemiology, Clinical Manifestations, and Prevention.
Frank MG, Weaver G, Raabe V; State of the Clinical Science Working Group of the National Emerging Pathogens Training; Education Center’s Special Pathogens Research Network2; State of the Clinical Science Working Group of the National Emerging Pathogens Training Education Center’s Special Pathogens Research Network. Frank MG, et al. Emerg Infect Dis. 2024 May;30(5):854-863. doi: 10.3201/eid3005.231647. Emerg Infect Dis. 2024. PMID: 38666548 Free PMC article. Review.
SARS-CoV-2 RNA and nucleocapsid antigen are blood biomarkers associated with severe disease outcomes that improve in response to remdesivir.
Singh K, Rubenstein K, Callier V, Shaw-Saliba K, Rupert A, Dewar R, Laverdure S, Highbarger H, Lallemand P, Huang ML, Jerome KR, Sampoleo R, Mills MG, Greninger AL, Juneja K, Porter D, Benson CA, Dempsey W, El Sahly HM, Focht C, Jilg N, Paules CI, Rapaka RR, Uyeki TM, Lane HC, Beigel J, Dodd LE; Adaptive COVID-19 Treatment Trial (ACTT-1) Study Group Members. Singh K, et al. J Infect Dis. 2024 Apr 24:jiae198. doi: 10.1093/infdis/jiae198. Online ahead of print. J Infect Dis. 2024. PMID: 38657001
Immunomodulators for immunocompromised patients hospitalized for COVID-19: a meta-analysis of randomized controlled trials.
Siempos II, Kalil AC, Belhadi D, Veiga VC, Cavalcanti AB, Branch-Elliman W, Papoutsi E, Gkirgkiris K, Xixi NA, Kotanidou A, Hermine O, Porcher R, Mariette X; CORIMUNO-19 Collaborative Group; DisCoVeRy Study Group; ACTT-2 Study Group; ACTT-3 Study Group. Siempos II, et al. EClinicalMedicine. 2024 Feb 9;69:102472. doi: 10.1016/j.eclinm.2024.102472. eCollection 2024 Mar. EClinicalMedicine. 2024. PMID: 38361992 Free PMC article.
393 results